Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LADOGA: Durvalumab Plus Oleclumab in Unresectable Stage III NSCLC
NCT06606847Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Sep 2024
- Primary completion
- May 2026
- Countries
- 1
- Sponsor
- AstraZeneca
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Drugs
- oleclumab
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label, single-arm trial of oleclumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Progression-Free Survival at 12 months. Started Sep 2024; status: active, not recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Arm 1
durvalumab plus oleclumab as an IV infusions
03
Who it enrols
Adult patients with Stage III, unresectable NSCLC (EGFR/ALK wild-type) who have not progressed following definitive platinum-based chemoradiation therapy, with WHO PS 0-1.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Progression-Free Survival
Overall Survival
Objective Response Rate
Duration of Response
Time to Response
Beyond the preview
Go deeper on NCT06606847.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06606847.